Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564260 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL20681302 | 0.79 | ALDH1A1 (0.40) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL23569348 | 0.76 | CA2 (0.34) | CA2 | |
| SCHEMBL23569219 | 0.75 | CA2 (0.35) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL23569845 | 0.75 | KEAP1 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL23569424 | 0.75 | CA12 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL18701621 | 0.74 | LMNA (0.32) | PTGS2CA1CA2 | |
| SCHEMBL23569857 | 0.74 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL23569422 | 0.71 | CA1 (0.34) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2068726 | 0.67 | NPC1 (0.43) | PTGS2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |